
Kyverna Therapeutics, Inc.: updates and filings
Price
$4.26
November 20, 2026Market cap $257M
What Ploutos Investor adds for Kyverna Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 3 fiscal years, from 2023
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
November 2026
August 2026
July 2026
May 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 16, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 12, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 12, 2026Results of operationsForm8-K
- Oct 19, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Sep 24, 2026Regulation FD disclosureForm8-K
- Aug 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 11, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 11, 2026Results of operationsForm8-K
- Jul 29, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Jul 27, 2026Material agreement entered, Regulation FD disclosureForm8-K
- Jul 9, 2026Material agreement enteredForm8-K
- Jun 2, 2026Shareholder voteForm8-K
- May 18, 2026Officer or director change, other material eventsForm8-K
- May 12, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 12, 2026Results of operationsForm8-K
- May 4, 2026Other material eventsForm8-K
- Apr 22, 2026Regulation FD disclosureForm8-K
- Apr 22, 2026Regulation FD disclosureForm8-K
- Apr 20, 2026Regulation FD disclosureForm8-K
- Apr 13, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 13, 2026Additional annual meeting materialFormDEFA14A
- Apr 13, 2026Annual meeting proxy statementFormDEF 14A
- Apr 2, 2026FilingFormEFFECT
- Mar 31, 2026Correspondence with the SECFormCORRESP
- Mar 30, 2026Letter from the SECFormUPLOAD
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 16, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 12, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 12, 2026 | 8-K | Results of operations | Document |
| Oct 19, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Sep 24, 2026 | 8-K | Regulation FD disclosure | Document |
| Aug 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 11, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 11, 2026 | 8-K | Results of operations | Document |
| Jul 29, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Jul 27, 2026 | 8-K | Material agreement entered, Regulation FD disclosure | Document |
| Jul 9, 2026 | 8-K | Material agreement entered | Document |
| Jun 2, 2026 | 8-K | Shareholder vote | Document |
| May 18, 2026 | 8-K | Officer or director change, other material events | Document |
| May 12, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 12, 2026 | 8-K | Results of operations | Document |
| May 4, 2026 | 8-K | Other material events | Document |
| Apr 22, 2026 | 8-K | Regulation FD disclosure | Document |
| Apr 22, 2026 | 8-K | Regulation FD disclosure | Document |
| Apr 20, 2026 | 8-K | Regulation FD disclosure | Document |
| Apr 13, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 13, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 13, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Apr 2, 2026 | EFFECT | Filing | Document |
| Mar 31, 2026 | CORRESP | Correspondence with the SEC | Document |
| Mar 30, 2026 | UPLOAD | Letter from the SEC | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Oct 5, 2023.
The full analysis
What do Kyverna Therapeutics's filings show?
The filings are where every one of Kyverna Therapeutics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.